This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carol H. Wysham, ...

Purpose: A review of the significant findings related to the use of the thiazolidinediones (TZDs) in the treatment of patients with type 2 diabetes mellitus and heart failure was conducted. Summary: ...

Add Yahoo as a preferred source to see more of our stories on Google. Close-Up Of Donated Blood In Bag Your blood type affects everything, from a predisposition to certain diseases to your heart ...

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had ...

Data are lacking about the relationship between type 2 diabetes and the risks of heart failure (HF) among people with elevated cardiac biomarkers. This information is particularly scant among Black ...

Type 1 diabetics have a lower risk of experiencing a cardiovascular event such as a stroke or heart attack than type 2 diabetics, a new study has found. It highlights the fundamental difference ...

USA: Oral semaglutide may lower the risk of heart failure-related events in people with type 2 diabetes who already have heart failure, without increasing serious adverse events, a secondary analysis ...

Oral semaglutide reduces risk for heart failure events among patients with T2D and preexisting heart failure, according to the SOUL trial.

A @HopkinsMedicine-led study offers strong evidence that adults with coexisting prediabetes and hypertension are at a higher ...

Type 2 diabetes doesn’t just raise the risk of heart disease—it physically reshapes the heart itself. Researchers studying donated human hearts found that diabetes disrupts how heart cells produce ...

Obesity, diabetes and high blood pressure are fueling increases in cardiovascular disease, even among much younger women, the American Heart Association said.

Oral semaglutide reduced the number of significant heart failure-related events in people with type 2 diabetes (T2D), a new study has found. The largest benefit was observed in a particularly ...